Amgen Reported Results of ENZ110 (biosimilar, romiplostim) for the Treatment of Chronic Immune Thrombocytopenia
Shots:
- The company highlighted the study results published in the Indian Journal of Hematology and Blood Transfusion evaluating biosimilar romiplostim ENZ110 vs innovator romiplostim (Nplate) in a ratio (1:1) in patients aged 18-65yrs. with chronic immune thrombocytopenia for 12wks.
- The results showed noninferiority and comparable safety and immunogenicity between biosimilar romiplostim (ENZ110) and innovator romiplostim (Nplate), platelet response of >50 x 109/L was achieved in 85.3% vs 75.0% in per protocol population over 12wks.; 83.8% vs 76.9% in ITT population
- TEAEs (65.4%), AEs were recorded in 66.7% vs 61.5%, rates of patients who have at least 1 AE were similar b/w groups, treatment-emergent anti-drug Ab (5.71% vs 9.09%)
Ref: Centerforbiosimilar | Image: Amgen
Related News:- Amgen Files BPCIA Complaint Against Sandoz Over Denosumab Biosimilar
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
